In this paper, we provide epidemiological information on patients with bleeding disorders as well as an estimate of FVIII and FIX products required in Italy to treat HA and HB patients using data collected in 2015 by the Italian registry of bleeding disorders. This evidence concerns the gene F8 and hemorrhagic disease.